Bulletin
Investor Alert

Market Pulse Archives

Nov. 17, 2021, 6:13 a.m. EST

Merck and Ridgeback Biotherapeutics to present Phase 3 data from COVID antiviral at ASTMH meeting at 9. a.m.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Merck /zigman2/quotes/209956077/composite MRK -0.95% and partner privately held Ridgeback Biotherapeutics will present data from a Phase 3 trial of their COVID-19 antiviral molnupiravir at the American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting taking place virtually starting later Wednesday. "Poster data will be available on Wednesday, Nov. 17 at 9 a.m. ET and presented during Poster Session C from 11 a.m.-12:30 p.m. ET on Saturday, Nov. 20.," the companies said in a joint statement. There are high hopes for the drug, which can be taken at home, while existing COVID treatments have to be administered by intravenous or subcutaneous infusion in a clinical setting. The treatment has already been authorized for use in the U.K. in treating mild-to-moderate COVID-19 in adults who have tested positive and who have at least one risk factor for developing severe illness. The company has sought regulatory approval in the U.S., EU, Japan and other countries. Merck has agreed to make molnupiravir available to lower income countries and will allow generic companies to make it. Merck shares were slightly lower premarket but have gained 8% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.89% has gained 25%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 79.98
-0.77 -0.95%
Volume: 18.46M
Jan. 21, 2022 4:02p
P/E Ratio
28.24
Dividend Yield
3.45%
Market Cap
$202.03 billion
Rev. per Employee
$660,851
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,397.94
-84.79 -1.89%
Volume: 3.20B
Jan. 21, 2022 4:52p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.